Peng Wei, Li Chuan, Zhu Wen-Jiang, Wen Tian-Fu, Yan Lv-Nan, Li Bo, Wang Wen-Tao, Yang Jia-Yin
Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, China.
Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, China.
J Surg Res. 2015 Apr;194(2):464-470. doi: 10.1016/j.jss.2014.12.021. Epub 2014 Dec 17.
There is limited evidence concerning the postoperative platelet to lymphocyte ratio change (ΔPLR) in relation to the prognosis of hepatocellular carcinoma (HCC). This study was designed to evaluate the prognostic value of ΔPLR in patients with hepatitis B virus (HBV)-related small HCC who underwent liver resection.
We retrospectively reviewed 219 patients with HBV-related small HCC who underwent liver resection between February 2007 and April 2013. The patients were divided into two groups as follows: group A (ΔPLR ≥2.875, n = 94) and group B (ΔPLR <2.875, n = 125), according to receiver operating characteristic analysis. Demographic, clinical, and follow-up data were analyzed, and multivariate analysis was used to identify prognostic factors.
The 1-, 3-, and 5-y overall survival (OS) rates were 90.5%, 72.3%, and 42.1%, respectively, in group A and 98.1%, 89.5%, and 86.4%, respectively, in group B (P < 0.001). Correspondingly, the 1-, 3-, and 5-y recurrence-free survival (RFS) rates were 57.5%, 36.1%, and 22.8%, respectively, in group A and 84.3%, 62.4%, and 55.4%, respectively, in group B (P < 0.001). Multivariate analysis showed that ΔPLR was an independent prognostic factor for both OS (P < 0.001, hazard ratio = 5.452, 95% confidence interval 2.592-11.467) and RFS (P < 0.001, hazard ratio = 2.191, 95% confidence interval 1.4611-3.288).
ΔPLR was an independent prognostic factor for OS and RFS in patients with HBV-related small HCC who underwent liver resection.
关于肝细胞癌(HCC)预后与术后血小板与淋巴细胞比值变化(ΔPLR)的证据有限。本研究旨在评估ΔPLR对接受肝切除的乙型肝炎病毒(HBV)相关小肝癌患者的预后价值。
我们回顾性分析了2007年2月至2013年4月期间接受肝切除的219例HBV相关小肝癌患者。根据受试者工作特征分析,将患者分为两组:A组(ΔPLR≥2.875,n = 94)和B组(ΔPLR < 2.875,n = 125)。分析人口统计学、临床和随访数据,并采用多因素分析确定预后因素。
A组1年、3年和5年总生存率(OS)分别为90.5%、72.3%和42.1%,B组分别为98.1%、89.5%和86.4%(P < 0.001)。相应地,A组1年、3年和5年无复发生存率(RFS)分别为57.5%、36.1%和22.8%,B组分别为84.3%、62.4%和55.4%(P < 0.001)。多因素分析显示,ΔPLR是OS(P < 0.001,风险比= 5.452,95%置信区间2.592 - 11.467)和RFS(P < 0.001,风险比= 2.191,95%置信区间1.4611 - 3.288)的独立预后因素。
ΔPLR是接受肝切除的HBV相关小肝癌患者OS和RFS的独立预后因素。